A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease - Trial NCT05744401
Access comprehensive clinical trial information for NCT05744401 through Pure Global AI's free database. This Phase 2 trial is sponsored by Alector Inc. and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 190 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Alector Inc.
Timeline & Enrollment
Phase 2
Jan 04, 2023
Dec 01, 2025
Primary Outcome
Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs.,Safety and tolerability as measured by the number of MRI abnormalities.,Effect of Immunogenicity as measured by ADAs titers.
Summary
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in
 participants with Early Alzheimer's Disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05744401
Non-Device Trial